Log In
Print
BCIQ
Print
Print this Print this
 

Anti-miR-122, RG-101

  Manage Alerts
Collapse Summary General Information
Company Regulus Therapeutics Inc.
DescriptionGalNAc-conjugated antagonist targeting miR-122
Molecular Target MicroRNA-122 (miR-122)
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: microRNA
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today